|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1155 F STREET, NW, #1150 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Plainsboro |
State | NJ |
Zip Code | 08536 |
Country | USA |
|
5. Senate ID# 284790-12
|
||||||||
|
6. House ID# 369030000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Christopher Porter, Chief Government Affairs Officer |
Date | 10/16/2014 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards;
diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; S.RES 489, S.RES.242 and H.RES.313 Supporting the goals and ideals of "Growth Awareness Week" and the MAGIC Foundation; H.R. 4302, Protecting Access to Medicare Act; S. 2157, Commonsense Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014 (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 3322, Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Omnibus; H. Con Res. 25 House Budget Resolution; H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program);
H.J. Res. 59 FY14 Continuing Appropriations Resolution (contains Bipartisan Budget Act of 2013). H Con Res 96 the House FY 2015 Budget; H.J.Res 124 Continuing Appropriations Resolution FY15
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Actof 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare);
Medicare diabetes screening generally; S. 1184 and H.R. 2415 Treat and Reduce Obesity Act of 2013 and obesity medication coverage generally; Diabesity amendment to S. 1871 SGR Repeal and Medicare Beneficiary Access; Physician Quality and Reporting System (PQRS)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
R&D Tax Credit;H.R. 2052; S. 1023 Global Investment in American Jobs Act of 2013; corporate tax inversion
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues related to insulin pen safety and access in the VA
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 3309 Innovation Act and S. 1720 Patent Transparency and Improvements Act of 2013 (patent litigation and assertion); demand letters
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Porter |
|
|
|
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amy |
Thienel |
|
|
|
Tricia |
Brooks |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
9 |
|
||||||
2 |
|
10 |
|
||||||
3 |
|
11 |
|
||||||
4 |
|
12 |
|
||||||
5 |
|
13 |
|
||||||
6 |
|
14 |
|
||||||
7 |
|
15 |
|
||||||
8 |
|
16 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
Novo Nordisk Fonden (Foundation) |
|
|
0.00 | 25.5 % | ||||||||||
Novo A/S |
|
|
0.00 | 25.5 % | ||||||||||
Novo Nordisk A/S |
|
|
0.00 | 100 % |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 9 | 17 |
2 | 10 | 18 |
3 | 11 | 19 |
4 | 12 | 20 |
5 | 13 | 21 |
6 | 14 | 22 |
7 | 15 | 23 |
8 | 16 | 24 |